Home › Research › Mild cognitive impairment
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ et al.. Neurology, 2009-12-30
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. Objective To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. Methods A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. Results The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Abeta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. Conclusion The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.
What this study adds
Evidence grade: Low
The record lists 819 participants. In this group, people with MCI progressed to dementia "at a rate of 16.5% per year", and baseline spinal-fluid Abeta-42 "separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures". Reported effect size: 16.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., et al. (2010). Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. https://doi.org/10.1212/wnl.0b013e3181cb3e25
Vancouver
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010. doi:10.1212/wnl.0b013e3181cb3e25. PMID: 20042704.
BibTeX
@article{petersen2010-20042704,
author = {Petersen, R. C. and Aisen, P. S. and Beckett, L. A. and Donohue, M. C. and Gamst, A. C. and Harvey, D. J. and Jack, C. R. and Jagust, W. J. and others},
title = {{Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization}},
journal = {Neurology},
year = {2010},
doi = {10.1212/wnl.0b013e3181cb3e25},
pmid = {20042704},
url = {https://doi.org/10.1212/wnl.0b013e3181cb3e25}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD.
Why it matters
This paper describes the 819 people (229 cognitively normal, 398 with mild cognitive impairment, 192 with mild Alzheimer's) who were followed for 12 months in the Alzheimer's Disease Neuroimaging Initiative, so that later studies could test brain-scan and fluid biomarkers against them. In this group, people with MCI progressed to dementia "at a rate of 16.5% per year", and baseline spinal-fluid Abeta-42 "separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures". It is an observational description of one research cohort over one year. It tests no treatment, and about half the MCI group were already on antidementia drugs.
Study details
- Participants819
- Effect size16.5%
- Evidence strengthLow
How this study scored 68/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 819 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 2,588 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 143.8 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 5 / 6 | Cited 26.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 5 / 6 | Cited by 188 other studies in this library |
| Still being cited | 4 / 4 | Cited 1,034 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Michael Walter Weiner: h-index 171 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California San Diego: institution h-index 1,852 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20042704) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
188 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Mild cognitive impairment from nearby years
Also in Mild cognitive impairment
76 studies in the library are filed under Mild cognitive impairment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Mild cognitive impairment hub.